Ha habido 50 transacciones internas recientes registradas para Soleno Therapeutics, Inc. (SLNO), incluyendo 23 compras y 22 ventas. El total de compras internas fue valorado en $21.22M y el total de ventas internas en $129.87M.
Internos destacados con actividad reciente incluyen Manning Meredith, Huang Michael F., Fulk Jennifer. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — SLNO
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-03-27 |
Manning Meredith |
Chief Commercial Officer |
Venta Informativa |
558 |
$31.72 |
$17.7K |
64,507 |
| 2026-03-27 |
Huang Michael F. |
Sr. VP of Clinical Development |
Venta Informativa |
488 |
$31.72 |
$15.48K |
39,823 |
| 2026-03-02 |
Fulk Jennifer |
Officer |
Desconocido |
- |
- |
- |
- |
| 2026-03-02 |
Fulk Jennifer |
Chief Financial Officer |
Concesión de RSU |
39,200 |
- |
- |
39,200 |
| 2026-01-21 |
Mackaness James H |
Chief Financial Officer |
Concesión de RSU |
32,800 |
$43.65 |
$1.43M |
32,800 |
| 2026-01-21 |
Anish Bhatnagar |
Chief Executive Officer |
Concesión de RSU |
131,400 |
$43.65 |
$5.74M |
131,400 |
| 2026-01-21 |
Yen Kristen |
See Remarks |
Concesión de RSU |
11,900 |
$43.65 |
$519.44K |
11,900 |
| 2026-01-21 |
Manning Meredith |
Chief Commercial Officer |
Concesión de RSU |
32,800 |
$43.65 |
$1.43M |
32,800 |
| 2026-01-21 |
Hirano Patricia C |
See Remarks |
Concesión de RSU |
11,900 |
$43.65 |
$519.44K |
11,900 |
| 2026-01-21 |
Norrett Kevin |
Chief Business Officer |
Concesión de RSU |
4,000 |
$43.65 |
$174.6K |
4,000 |
| 2026-01-21 |
Joshi Manher |
Chief Development Officer |
Concesión de RSU |
4,700 |
$43.65 |
$205.16K |
4,700 |
| 2026-01-21 |
Huang Michael F. |
Sr. VP of Clinical Development |
Concesión de RSU |
11,900 |
$43.65 |
$519.44K |
11,900 |
| 2025-12-15 |
Mackaness James H |
Chief Financial Officer |
Retención Fiscal de RSU |
2,013 |
$49.95 |
$100.55K |
103,163 |
| 2025-12-15 |
Anish Bhatnagar |
Chief Executive Officer |
Donación (Otorgada) |
100,000 |
- |
- |
469,456 |
| 2025-12-15 |
Yen Kristen |
See Remarks |
Retención Fiscal de RSU |
904 |
$49.95 |
$45.15K |
27,239 |
| 2025-12-15 |
Manning Meredith |
Chief Commercial Officer |
Retención Fiscal de RSU |
1,922 |
$49.95 |
$96K |
43,429 |
| 2025-12-15 |
Hirano Patricia C |
See Remarks |
Retención Fiscal de RSU |
904 |
$49.95 |
$45.15K |
12,302 |
| 2025-12-15 |
Huang Michael F. |
Sr. VP of Clinical Development |
Retención Fiscal de RSU |
812 |
$49.95 |
$40.56K |
36,005 |
| 2025-11-17 |
Norrett Kevin |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-11-17 |
Norrett Kevin |
Chief Business Officer |
Concesión de RSU |
14,286 |
- |
- |
14,286 |
| 2025-11-10 |
Joshi Manher |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-11-10 |
Joshi Manher |
Chief Development Officer |
Concesión de RSU |
16,071 |
- |
- |
16,071 |
| 2025-10-13 |
Hahn Mark W |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-10-13 |
Hahn Mark W |
Director |
Concesión de RSU |
10,046 |
- |
- |
10,046 |
| 2025-07-01 |
Hirano Patricia C |
See Remarks |
Venta Informativa |
3,830 |
$82.76 |
$316.97K |
13,206 |
| 2025-06-24 |
Hirano Patricia C |
See Remarks |
Ejercicio de Opciones (Venta) |
266 |
$44.25 |
$11.77K |
- |
| 2025-06-05 |
Harris William G |
Director |
Concesión de RSU |
3,991 |
- |
- |
19,392 |
| 2025-06-05 |
Pauls Matthew |
Director |
Concesión de RSU |
3,991 |
- |
- |
10,491 |
| 2025-06-05 |
Bir Dawn Carter |
Director |
Concesión de RSU |
3,991 |
- |
- |
16,991 |
| 2025-06-05 |
Volck Birgitte |
Director |
Concesión de RSU |
3,991 |
- |
- |
17,536 |
| 2025-06-05 |
Sinclair Andrew |
Director |
Concesión de RSU |
3,991 |
- |
- |
10,491 |
| 2025-04-01 |
Hirano Patricia C |
See Remarks |
Venta Informativa |
3,782 |
$70.11 |
$265.16K |
27,036 |
| 2025-03-28 |
Vivo Opportunity, Llc |
10 Percent Owner |
Venta Informativa |
333,557 |
$70.60 |
$23.55M |
4,458,294 |
| 2025-03-28 |
Pauls Matthew |
Director |
Venta Informativa |
5,937 |
$71.55 |
$424.8K |
6,500 |
| 2025-03-28 |
Hirano Patricia C |
See Remarks |
Ejercicio de Opciones (Venta) |
2,691 |
$33.60 |
$90.42K |
18,842 |
| 2025-03-27 |
Vivo Opportunity, Llc |
10 Percent Owner |
Venta Informativa |
1,100,000 |
$67.80 |
$74.58M |
4,791,851 |
| 2025-03-27 |
Mackaness James H |
Chief Financial Officer |
Ejercicio de Opciones (Venta) |
5,000 |
$2.60 |
$12.98K |
- |
| 2025-03-27 |
Anish Bhatnagar |
Chief Executive Officer |
Ejercicio de Opciones (Venta) |
16,666 |
$25.05 |
$417.48K |
- |
| 2025-03-27 |
Yen Kristen |
See Remarks |
Ejercicio de Opciones (Venta) |
4,888 |
$5.10 |
$24.93K |
2,445 |
| 2025-03-27 |
Manning Meredith |
Chief Commercial Officer |
Venta Informativa |
37,000 |
$67.04 |
$2.48M |
45,351 |
| 2025-03-27 |
Hirano Patricia C |
See Remarks |
Ejercicio de Opciones (Venta) |
6,000 |
$24.00 |
$144K |
- |
| 2025-03-27 |
Huang Michael F. |
Sr. VP of Clinical Development |
Venta Informativa |
10,000 |
$70.03 |
$700.33K |
36,817 |
| 2025-03-26 |
Vivo Opportunity, Llc |
10 Percent Owner |
Venta Informativa |
400,000 |
$65.80 |
$26.32M |
5,891,851 |
| 2025-01-21 |
Mackaness James H |
Chief Financial Officer |
Concesión de RSU |
31,000 |
$49.17 |
$1.52M |
31,000 |
| 2025-01-21 |
Anish Bhatnagar |
Chief Executive Officer |
Concesión de RSU |
115,600 |
$49.17 |
$5.68M |
115,600 |
| 2025-01-21 |
Yen Kristen |
See Remarks |
Concesión de RSU |
13,800 |
$49.17 |
$678.55K |
13,800 |
| 2025-01-21 |
Manning Meredith |
Chief Commercial Officer |
Concesión de RSU |
29,200 |
$49.17 |
$1.44M |
29,200 |
| 2025-01-21 |
Hirano Patricia C |
See Remarks |
Concesión de RSU |
13,800 |
$49.17 |
$678.55K |
13,800 |
| 2025-01-21 |
Huang Michael F. |
Sr. VP of Clinical Development |
Concesión de RSU |
13,800 |
$49.17 |
$678.55K |
13,800 |
| 2025-01-03 |
Mackaness James H |
Chief Financial Officer |
Venta Informativa |
3,791 |
$46.18 |
$175.05K |
111,298 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
